Abstract
FGFR inhibitors represent a new and promising therapeutic approach to urothelial cancer (UC). Erdafitinib (Balversa(C)) was the first FGFR inhibitor a......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
